

23 March 2011 EMA/CVMP/37837/2011 Veterinary Medicines and Product Data Management

# Committee for Medicinal Products for Veterinary Use

Monthly report of application procedures, guidelines and related documents March 2011

The CVMP monthly report includes statistical data for the current and previous two years on scientific advice, initial evaluations, variations, line extensions, renewals, MRLs initial evaluations and MRLs extensions/modifications and arbitration and referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted guidelines and other public documents.

# Applications for medicinal products for veterinary use and maximum residue limits (MRLs)

Scientific advice requests										
	95-08 2009 2010 2011 Tota									
Submitted	69	11	21	2	103					
Advice given	Advice given         65         8         18         5         96									

Initial evaluation								
	95-08	2009	2010	2011	Total			
Full	110	14	16	2	142			
(Submitted)								
Abridged/	10	1	2	0	13			
generics								
(Submitted)								
Withdrawals	12	0	1	0	13			
Positive	91	13	14	6	124			
opinions								
Negative	1	0	0	0	1			
opinions								

Marketing authorisations								
95-08 2009 2010 2011 Total								
Granted	88	12	9	8	117			
Withdrawals	2	0	4	0	6			
Not renewed	2	0	0	0	2			

Extensions									
	95-08	2009	2010	2011	Total				
Submitted	60	12	3	1	76				
Withdrawals	2	1	1	0	4				
Positive	40	7	8	1	56				
opinions									
Negative	0	0	0	0	0				
opinions									

An agency of the European Union

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8447 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



© European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.

Variations – applications submitted								
	95-08	2009	2010	2011	Total			
Type IA	339	32	76	18				
Type IB	557	41	63	10				
					579			
Type II	210	40	26	4	280			
Transfers	11	3	8	2	24			

Renewals								
	95-08	2009	2010	2011	Total			
Submitted	50	18	7	4	79			
Positive	48	17	8	1	74			
opinions								
Negative	0	0	0	0	0			
opinions								

Arbitrations and Community referrals								
	95-08	2009	2010	2011	Total			
Referrals submitted	38	9	12	2	61			
Opinions reached <sup>1</sup>	20	15 (5)	11 (1)	0	46 (6)			

<sup>1</sup> Re-examination of opinions in brackets

Substances considered as not falling within the scope of Regulation (EC) No 470/2009					
2011 Total					
Submitted	1	1			
Agreed	6	6			
Scientific advice recommended	0	0			

MUMS/ Limited market classification						
	2011	Total				
Positive with financial incentives	0	0				
Positive without financial	6	6				
incentives						
Negative	1	1				

Establishment of MRLs for new substances									
	95-08 2009 2010 2011 Total								
Submitted	66	4	3	1	74				
Withdrawals	5	0	0	0	5				
Positive	54	2	2	2	60				
opinions <sup>2</sup>									
Negative	7	0	0	0	7				
opinions <sup>3</sup>									

Extensions / modifications/extrapolations of MRLs									
	95-08 2009 2010 2011 Total								
Submitted	98	2	10	1	111				
Withdrawals	4	0	0	0	4				
Positive	113	3	3	1	120				
opinions <sup>3</sup>									
Negative	6	0	0	0	6				
opinions									
Extrapolations	50	0	0	0	50				

<sup>2</sup> Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits <sup>3</sup> Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously octablished established

## CVMP opinions in 2011 on medicinal products for veterinary use

Positive opinions

Pro	oduct	•	Marketing	Th	erapeutic area	ΕN	IA/CVMP	Eu	ropean Commission
•	Invented name INN		authorisation holder	•	Target species Summary of indication	•	Validation Opinion Active time Clock stop	•	Opinion received Date of decision Notification Official Journal
•	CaniLeish	•	Virbac S.A.	•	Dogs Vaccine against Leishmania infection	•	17/03/2010 12/01/2011 210 91	•	13/01/2011 14/03/2011
•	ZULVAC 1 + 8 Ovis	•	Pfizer Limited	•	Sheep Vaccine for prevention of viraemia caused by Bluetongue Virus serotypes 1 and 8	•	18/03/2010 12/01/2011 180 119	•	13/01/2011 14/03/2011
•	BLUEVAC BTV8	•	CZ Veterinaria S.A	•	Cattle, sheep Vaccine for active immunisation against bluetongue disease	•	17/01/2009 09/02/2011 180 511	•	10/02/2011
•	Procox Emodepside and toltrazuril	•	Bayer Animal Health GmbH	•	Dogs Treatment of dogs when mixed parasitic infections, caused by certain specific roundworms and coccidia are suspected or demonstrated	•	16/02/2010 09/02/2011 210 148	•	11/02/2011
•	Veraflox Pradofloxacin	•	Bayer Animal Health GmbH	•	Dogs, cats Treatment for dogs and cats with particular infections caused by certain specific and susceptible pathogens	• • (re	19/05/2009 14/07/2010 205 217 09/02/2011 e-consideration)	•	11/02/2011

Pro	oduct	•	Marketing	Th	erapeutic area	ΕM	IA/CVMP	Eu	ropean Commission
•	Invented name INN		authorisation holder	•	Target species Summary of indication	•	Validation Opinion Active time	•	Opinion received Date of decision Notification
						•	Clock stop	•	Official Journal
•	Zuprevo Tildipirosin	•	Intervet International BV	•	Pigs, cattle Treatment of bacterial infections in the respiratory tract in pigs and cattle	•	16/02/2010 08/03/2011 210 177	•	10/03/2011
•	CERTIFECT Fipronil, (S)- methoprene, amitraz	•	MERIAL SAS	•	Dogs Treatment and prevention of infestations with ticks, alone or in association with fleas and/or chewing lice	•	16/03/2010 09/03/2011 210 148	•	10/03/2011

## **CVMP** opinions in 2011 on establishment of MRLs for new substances

Positive opinions

<ul><li>Substance</li><li>INN</li></ul>	<ul><li>Therapeutic area</li><li>Target species</li></ul>	EMA/CVMP <ul> <li>Validation</li> <li>Opinion</li> <li>Active time</li> <li>Clock stop</li> </ul>	European Commission <ul> <li>Opinion received</li> <li>Date of regulation</li> <li>Official Journal</li> </ul>
<ul> <li>Methylpredni – solone</li> <li>(after provisional MRLs)</li> </ul>	Bovine	<ul> <li>n/a</li> <li>12/01/2011</li> <li>90</li> <li>0</li> </ul>	• 27/01/2011
Octenidine     dihydrochloride	All mammalian food     producing species	<ul> <li>11/08/2009</li> <li>08/02/2011</li> <li>210</li> <li>246</li> </ul>	• 21/02/2011
<ul> <li>Monepantel</li> <li>(after provisional MRLs)</li> </ul>	Caprine	<ul> <li>n/a</li> <li>09/03/2011</li> <li>90</li> <li>0</li> </ul>	•

## Arbitrations and Community referrals in 2011

Type of referral	<ul><li>Date of clock start</li><li>CVMP opinion</li></ul>	Product name     INN
Referral under Art. 34 of Directive 2001/82/EC	• 11/11/2009	<ul><li>Fortekor vet and associated names</li><li>Benazepril hydrochloride</li></ul>
Referral under Art. 34 of Directive 2001/82/EC	• 14/04/2010	<ul><li>Synulox Lactating Cow and associated names</li><li>Amoxicillin, clavulanic acid, prednisolone</li></ul>
Referral under Art. 33(4) of Directive 2001/82/EC	• 14/07/2010	<ul><li>Combimox Lactating Cow</li><li>Amoxicillin, clavulanic acid, prednisolone</li></ul>
Referral under Art. 33(4) of Directive 2001/82/EC	• 14/07/2010	<ul><li>Nisamox Lactating Cow</li><li>Amoxicillin, clavulanic acid, prednisolone</li></ul>
Referral under Art. 33(4) of Directive 2001/82/EC	• 14/07/2010	<ul><li>Combisyn Lactating Cow</li><li>Amoxicillin, clavulanic acid, prednisolone</li></ul>
Referral under Art. 34 of Directive 2001/82/EC	• 14/07/2010	<ul><li>Doxycycline 50% WSP and associated names</li><li>Doxycycline hyclate</li></ul>
Referral under Art. 34 of Directive 2001/82/EC	• 14/07/2010	<ul> <li>Doxyfar 50% WSP and associated names</li> <li>Doxycycline hyclate</li> </ul>

Type of referral	<ul><li>Date of clock start</li><li>CVMP opinion</li></ul>	Product name     INN
Referral under Art. 34 of Directive 2001/82/EC	• 09/11/2010	<ul> <li>Baytril 10% oral solution and associated names</li> <li>Enrofloxacin</li> </ul>
Referral under Art. 33(4) of Directive 2001/82/EC	• 09/02/2011	<ul><li>Clavudale 50 mg tablet for cats and dogs</li><li>Amoxicillin and clavulanic acid</li></ul>
Referral under Art. 35 of Directive 2001/82/EC	• 09/03/2011	<ul> <li>Veterinary medicinal products containing active substances belonging to the class of flukicides for which no MRL has been established in milk</li> </ul>

## Guidelines and working documents in 2011

#### **CVMP Environmental Risk Assessment**

Reference number	Document title	Status
EMA/CVMP/ERA/147844/2011	Reflection paper on the testing strategy and risk assessment for plants	Adopted for consultation, March 2011 (End of consultation 30 June 2011)
EMA/CVMP/ERA/430327/2009	Guideline on determining the fate of veterinary medicinal products in manure	Adopted March 2011

#### **CVMP** Immunologicals

Reference number	Document title	Status
EMA/CVMP/IWP/206555/2010	Guideline on requirements for the production and control of immunological veterinary medicinal products	Adopted for consultation, March 2011 (End of consultation 30 September 2011)
EMA/CVMP/IWP/314550/2010	Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines	Adopted for consultation, March 2011 (End of consultation 30 September 2011)

#### **CVMP** Pharmacovigilance

Reference number	Document title	Status
EMA/CVMP/PhVWP/471721/2006	Recommendation on the basic surveillance of EudraVigilance Veterinary (EVVet) data	Adopted February 2011
EMA/CVMP/PhVWP/44873/2011	Public bulletin - Veterinary pharmacovigilance for 2010	Adopted February 2011

#### **CVMP Scientific Advisory Group on Antimicrobials**

Reference number	Document title	Status
EMA/CVMP/SAGAM/736964/2009	Reflection paper on meticillin- resistant <i>Staphylococcus</i> <i>pseudintermedius</i> (MRSP)	Adopted January 2011

#### General

Reference number	Document title	Status
EMA/347137/2010	Summary of procedures for consultation by CVMP of Scientific Advisory Groups (SAGs) and ad-hoc expert groups functioning as SAGs in relation to applications for authorisation for veterinary medicinal products	Adopted February 2011